Summary of Key Points Core Viewpoint The article discusses the share transfer process of Enwei Pharmaceutical Co., Ltd. (恩威医药) through a price inquiry method, detailing the procedures, pricing, and compliance with regulatory requirements. Group 1: Inquiry Transfer Overview - The inquiry transfer involves the transfer of 4,000,000 shares, representing 3.89% of the company's total share capital, with a transfer price set at 26.54 yuan per share, totaling 106,160,000 yuan [10][20][22]. - The transfer was conducted by CITIC Securities, which acted as the organizing broker for the inquiry transfer [1][21]. Group 2: Pricing and Allocation Principles - The price floor for the inquiry transfer was determined to be no less than 70% of the average trading price of Enwei Pharmaceutical shares over the 20 trading days prior to January 26, 2026 [3][27]. - The allocation of shares was based on a priority system that favored higher subscription prices, followed by subscription quantities and the order of receipt of subscription forms [4][5]. Group 3: Compliance and Regulatory Adherence - The inquiry transfer process was confirmed to be legal and compliant with various regulations, including the Company Law and Securities Law of the People's Republic of China [11][17]. - CITIC Securities conducted a thorough qualification review of both the transferor and transferee, ensuring that all parties met the necessary criteria for participation in the inquiry transfer [14][15]. Group 4: Investor Participation - A total of 451 institutional investors received the subscription invitation, including 80 fund companies, 54 securities firms, and 250 private fund managers [7][28]. - The inquiry transfer received 32 valid subscription forms during the designated period, indicating strong interest from institutional investors [8][28]. Group 5: Conclusion and Future Implications - The transfer will not change the controlling shareholder or the actual controller of Enwei Pharmaceutical, ensuring stability in the company's governance structure [20][32]. - The shares acquired through this inquiry transfer are subject to a six-month lock-up period, preventing immediate resale by the investors [20][32].